Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652297 | 1.00 | OPRL1 (0.44) | OPRL1CTRB1TSHRHTTFASN | |
| SCHEMBL10420330 | 1.00 | OPRL1 (0.44) | OPRL1CTRB1TSHRHTTFASN | |
| SCHEMBL7838610 | 1.00 | OPRL1 (0.44) | OPRL1CTRB1TSHRHTTFASN | |
| SCHEMBL6875994 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL740389 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL740390 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL740391 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL13172946 | 0.86 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL13534719 | 0.85 | OPRL1 (0.42) | OPRL1CTRB1FASN | |
| SCHEMBL10510512 | 0.84 | CYP2D6 (0.47) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9169744-A | — | — | None | — | — | JP | disclosed |
| US-6806384-B2 | VIA TREATING N-CARBAMATE-PROTECTED BETA-AMINOEPOXIDE WITH ACID FORMING 5-HYDROXYMETHYL-2-OXAZOLIDINONE, THEN OXIDIZING IN 2,2,6,6-TETRAMETHYL-1-PIPERIDINYLOXY AND HYPOCHLORITE FORMING 4-BENZYL-2-OXO-5-OXAZOLIDINECARBOXYLIC ACID; CRYSTALLIZATION | AJINOMOTO CO., INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| EP-1161416-B1 | ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS | ELAN PHARM INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6545160-B2 | Alpha-aminoacetic acid derivatives bind alpha 4 beta 7 integrin, useful for treatment of inflammatory diseases in mammalian patient, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020151722-A1 | Production method of beta-amino-alpha-hydroxycarboxylic acid | AJINOMOTO CO. INC (JP) | 2002-10-17 | — | — | US | disclosed |
| US-6410781-B1 | ANTIINFLAMMATORY AGENTS; ANTIHISTAMINES; ALZHEIMER'S DISEASE; | ELAN PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1161416-A1 | ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS | Elan Pharmaceuticals, Inc. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000051974-A1 | ALPHA-AMINOACETIC ACID DERIVATIVES USEFUL AS ALPHA 4 BETA 7 - RECEPTOR ANTAGONISTS | ELAN PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-5670653-A | Process for the manufacture of (4,5)-trans-oxazolidines | HOFFMANN-LA ROCHE INC. (US) | 1997-09-23 | — | — | US | disclosed |
| JP-H09169744-A | NEW PRODUCTION OF (4,5)-TRANS-OXAZOLIDINE | F HOFFMANN LA ROCHE AG | 1997-06-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151722-A1 | Production method of beta-amino-alpha-hydroxycarboxylic acid | HAO2, HAAO, DAO | OPRL1 2671/4885CTRB1 2273/4885TSHR 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.